slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 91,021-91,050
Pages 3,683
Rows per page 30
Component
91,021-91,050 of 110,471
08
Includes a table of revenue drivers and a stacked bar chart showing revenue composition.LKQ | Results Presentation Deck | 40 slides · LKQ
Conference presentation Investor relations 1 hit
15
Includes non-GAAP measure disclaimers and target conversion ranges.LKQ | Results Presentation Deck | 40 slides · LKQ
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
20
Includes footnotes for revenue and EPS definitions and reconciliation references.LKQ | Results Presentation Deck | 40 slides · LKQ
Conference presentation Investor relations Beat · SatisfactionLoop · So What Cascade1 hit
21
Includes detailed commentary on drivers for each segment's performance.LKQ | Results Presentation Deck | 40 slides · LKQ
Conference presentation Investor relations Beat · SatisfactionLoop · So What Cascade1 hit
22
Includes non-GAAP reconciliations and specific variance drivers for EPS.LKQ | Results Presentation Deck | 40 slides · LKQ
Conference presentation Investor relations Beat · SatisfactionLoop · So What Cascade1 hit
04
The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style layout to map drug candidates against clinical development stages.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a visual comparison between telomere targeting (left) and PD-1/PD-L1 checkpoint inhibition (right).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
13
The slide outlines a clinical trial process flow including randomization and expansion phases.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
15
The slide highlights that THIO has a better safety profile than standard chemotherapy, which typically has 70-80% incidence of Grade 3-5 side effects.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
19
Clinical trial data visualization showing patient-level outcomes over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
20
The chart tracks individual patient outcomes over time, including treatment status, response type, and study exit reasons.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
24
The slide presents two line charts showing tumor volume reduction and long-term survival/rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
25
The table compares three treatment regimens across four categories: Expected Efficacy, Safety Profile, Administration, and Trial of Reference.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
29
The chart shows a clear divergence between the control group (increasing tumor volume) and the THIO group (decreasing tumor volume to near zero).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
37
The slide uses a logo-grid and metric-grid to establish valuation context.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection to patient report generation.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
Uses a visual timeline/process flow to explain the disease progression.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
AA = Advanced Adenoma; CRC = Colorectal Cancer. Data sourced from JNCI 2022.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The slide outlines a multi-step diagnostic process involving FIT analysis and proprietary DNA/mRNA extraction.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
21
Includes a footer note about future feasibility studies for other tests.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
24
The slide uses a grid layout to present 10 key advisors with headshots, titles, and company logos.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
27
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit